C Caspar
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Moccia A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematol Oncol 2020; 39:196-204.
Dec 23, 2020Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Dec 23, 2020Hematol Oncol 2020; 39:196-204
Moccia A A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli Stefanie, Güsewell Sabine, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr Martin, Fischer N, Ghilardi G, Krasniqi F, Hitz Felicitas
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst T, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013; 92:1033-40.
Apr 17, 2013Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
Apr 17, 2013Ann Hematol 2013; 92:1033-40
Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst Th, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller T, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92.
Jul 1, 2008Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Jul 1, 2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller Thomas, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland